- Cool Tool – An Optimized, Chemically-Defined, Animal Component-Free Neural Basal MediumPosted 2 days ago
- Cool Tool – Lynx CDR Connectors to Improve Sterile Fluid Transfer in BiomanufacturingPosted 3 days ago
- Improving Glycosylation Patterns and Consistency Through Media OptimizationPosted 4 days ago
- Cool Tool – Online Cell Culture Media Formulation ToolPosted 1 week ago
- Video – Impact of Chemically Defined Media on Product QualityPosted 2 weeks ago
- Ask the Expert – Media Optimization Can Improve Glycosylation Patterns and Consistency to Impact Protein EfficacyPosted 2 weeks ago
- Digital Biomanufacturing Will Enable Tissue BioprintingPosted 3 weeks ago
- Video – When and Where to Optimize Cell Culture MediaPosted 4 weeks ago
- Cool Tool – SCOUT® technology reduces time to market and increases chance of success for biopharmaceutical productsPosted 4 weeks ago
- Pumping Iron – But Not in the gym: The Critical Roles of Transferrin in Cell Culture MediaPosted 4 weeks ago
Recombinant LONG R3IGF‐1 and rTransferrin Improved Growth and Productivity of Two Suspension Chinese Hamster Ovary Cell lines
Jinghui Qian, Rina Gandhi, Ariane Marolewski
LONG®R3IGF‐1 is a human IGF‐1 analog containing a 13 amino acid N‐terminal extension and a mutation at position 3. It activates the Type 1 IGF receptor, which is responsible for growth‐promoting and protein synthesis effects in CHO cells. A common growth factor supplement used in CHO media, insulin, acts primarily through the IGF‐R.
LONG®R3IGF‐1 has previously been shown to increase CHO productivity. However, past characterization studies used primarily DMEM/F12 media. As serum‐free media development has progressed, media have become richer and more complex. To establish the effect of LONG®R3IGF‐1 in media that meet today’s industry standards, the effect of LONG®R3IGF‐1 on the productivity of two antibody‐expressing cell lines was compared to that of insulin and no growth factor supplemented media. The studies were carried out in TPP Tubespin50mL bioreactor tubes. Media with LONG®R3IGF‐1 gave superior titers versus no growth factor or insulin in several instances. In addition, it was demonstrated that combination of LONG®R3IGF‐1 and rTransferrin gave higher titer than commercial ITS (rInsulin, rTransferrin, Selenium) solution in several modern commercial media types.
LONG®R3IGF‐1 is used at low, 10 –100 ng/mL, concentrations in cell culture and is currently used in several commercial antibody manufacturing processes. It represents a regulatory‐friendly method of enhancing serum‐free cell culture performance. LONG®R3IGF‐1 should, therefore, be considered as a media supplement to further optimize a protein‐free process or to replace insulin in existing processes.